Tumorigenesis News and Research RSS Feed - Tumorigenesis News and Research

Tumorigenesis is the process involved in the production of a new tumor or tumors.
New genetic evidence strengthens link between role of dietary fats with colon cancer progression

New genetic evidence strengthens link between role of dietary fats with colon cancer progression

Scientists have shown new genetic evidence that could strengthen the link between the role of dietary fats with colon cancer progression. [More]
Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine. [More]
Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes. [More]
Too little or too much of SRPK1 enzyme promotes cancer, shows research

Too little or too much of SRPK1 enzyme promotes cancer, shows research

Researchers at the University of California, San Diego School of Medicine have found that too little or too much of an enzyme called SRPK1 promotes cancer by disrupting a regulatory event critical for many fundamental cellular processes, including proliferation. [More]
IRB researchers identify dual role of p38 protein in colon cancer

IRB researchers identify dual role of p38 protein in colon cancer

A team headed by Angel R. Nebreda at the Institute for Research in Biomedicine identifies a dual role of the p38 protein in colon cancer. The study demonstrates that, on the one hand, p38 is important for the optimal maintenance of the epithelial barrier that protects the intestine against toxic agents, thus contributing to decreased tumour development. [More]
New report analyzes growth of CSCs market in developed nations

New report analyzes growth of CSCs market in developed nations

Research and Markets has announced the addition of the "Concise Analysis of the International Cancer Stem Cell Trends" report to their offering. [More]

Novel feedback provides mechanistic link between chronic inflammation and carcinogenesis

Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich have discovered a novel feedback mechanism that provides a mechanistic link between chronic inflammation and carcinogenesis. [More]
Research reveals 2 key mechanisms of oxidative stress regulation

Research reveals 2 key mechanisms of oxidative stress regulation

Regulation of oxidative stress is critical to cell survival. New preclinical research from Roswell Park Cancer Institute (RPCI) has revealed two key mechanisms by which oxidative stress is regulated in normal and cancerous cells. [More]
Scientists identify twenty proteins specifically secreted by primary effusion lymphoma cell lines

Scientists identify twenty proteins specifically secreted by primary effusion lymphoma cell lines

​Primary effusion lymphoma (PEL) is a rare B-cell neoplasm distinguished by its tendency to spread along the thin serous membranes that line body cavities without infiltrating or destroying nearby tissue. [More]
Erythropoietin may promote cancer cell proliferation and survival

Erythropoietin may promote cancer cell proliferation and survival

In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide. [More]

BeiGene doses first patient in Phase 1 study of BGB-283

BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway. [More]
Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease. [More]
Increased levels of protein HSET linked with worse breast cancer outcomes in African-Americans

Increased levels of protein HSET linked with worse breast cancer outcomes in African-Americans

Among African-American women with breast cancer, increased levels of the protein HSET were associated with worse breast cancer outcomes, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9. [More]
Gene discovered to play a part in one per cent of all cancers

Gene discovered to play a part in one per cent of all cancers

Researchers have identified a gene that drives the development of tumours in over one per cent of all cancer patients. This is the first time that the gene CUX1 has been broadly linked to cancer development. [More]
Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Cyclin D1, a protein that helps push a replicating cell through the cell cycle also mediates the processing and generation of mature microRNA, according to new research publishing November 29 in Nature Communications. The research suggests that a protein strongly implicated in human cancer also governs the non-protein-coding genome. The non-coding genome, previously referred to as junk DNA, makes up most of the human genome, and unlike the coding genome, varies greatly between species. [More]
Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond. [More]

Researchers discover relationship between TGFb signalling pathways and CXCR4 in HCC

​Researchers from the Biological clues of the invasive and metastatic phenotype group of the Bellvitge Biomedical Research Institute (IDIBELL) led by Isabel Fabregat have discovered the relationship between the TGFb signalling pathways and CXCR4 in hepatocellular carcinoma (HCC) . [More]
Study: Interactions between inflammation and changes in gut microbiota may result in colon tumors

Study: Interactions between inflammation and changes in gut microbiota may result in colon tumors

Transferring the gut microbes from a mouse with colon tumors to germ-free mice makes those mice prone to getting tumors as well, according to the results of a study published in mBio-, the online open-access journal of the American Society for Microbiology. [More]

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show. [More]
Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. [More]